LAKE FOREST, Ill., Feb. 23, 2012 — Hospira, Inc. (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, announced today that it has joined the Generic Pharmaceutical Association (GPhA). Hospira is dedicated to Advancing Wellness, a goal that matches well with the GPhA’s core purpose of bringing affordable medications to patients who need them.
“Hospira is pleased to announce our membership in the GPhA today,” said Thomas Moore, president, U.S., Hospira. “We commend the leadership shown by GPhA President Ralph Neas and the excellent staff he has assembled. GPhA is a strong industry trade association that will continue to work tirelessly to bring the safest, high-quality, lower cost generic drugs to patients and families who need them, and Hospira looks forward to working with the association on the many pressing issues facing our industry.”
“We are pleased to welcome Hospira to GPhA, and we look forward to their joining in the Association’s mission to improve the lives of consumers by providing timely access to affordable pharmaceuticals,” said Ralph G. Neas, President and CEO of GPhA. “Hospira’s products, like those of all our members, have enabled millions of Americans to obtain affordable treatments for critical conditions. Their input and participation will be a valuable asset for GPhA as we move into this new and exciting time for our industry.”
As the leading provider of generic injectables in the United States with the broadest and deepest portfolio of low-cost, safe and effective products, Hospira’s specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. Therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 78 percent of the prescriptions dispensed in the United States but consume just 25 percent of the total drug spending. Additional information is available at gphaonline.org.
Hospira, Inc. is the world’s leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.